دورية أكاديمية
Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study.
| العنوان: | Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. |
|---|---|
| المؤلفون: | Francavilla R; Department of Biomedicina dell'Età Evolutiva, Università degli Studi di Bari, Bari, Italy. rfrancavilla@libero.it, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL |
| المصدر: | Helicobacter [Helicobacter] 2008 Apr; Vol. 13 (2), pp. 127-34. |
| نوع المنشور: | Clinical Trial; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9605411 Publication Model: Print Cited Medium: Internet ISSN: 1523-5378 (Electronic) Linking ISSN: 10834389 NLM ISO Abbreviation: Helicobacter Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Malden, MA : Wiley-Blackwell, c1996- |
| مواضيع طبية MeSH: | Helicobacter pylori* , Pilot Projects*, Antigens, Bacterial/*analysis , Helicobacter Infections/*drug therapy , Limosilactobacillus reuteri/*physiology , Probiotics/*therapeutic use, Anti-Bacterial Agents ; Antigens, Bacterial/therapeutic use ; Double-Blind Method ; Feces/chemistry ; Feces/microbiology ; Gastritis/microbiology ; Gastritis/physiopathology ; Humans ; Urea/analysis |
| مستخلص: | Background: Several studies report an inhibitory effect of probiotics on Helicobacter pylori. Aim: To test whether Lactobacillus reuteri ATCC 55730 reduces H. pylori intragastric load in vivo, decreases dyspeptic symptoms, and affects eradication rates after conventional treatment. Materials and Methods: In a double-blind placebo-controlled study, 40 H. pylori-positive subjects were given L. reuteri once a day for 4 weeks or placebo. All underwent upper endoscopy, (13)C-urea breath test, and H. pylori stool antigen determination at entry and (13)C-urea breath test and H. pylori stool antigen (used as both qualitative and semiquantitative markers) after 4 weeks of treatment. Sequential treatment was administered subsequently to all. Results: In vivo, L. reuteri reduces H. pylori load as semiquantitatively assessed by both (13)C-urea breath test delta-value and H. pylori stool antigen quantification after 4 weeks of treatment (p < .05). No change was shown in patients receiving placebo. L. reuteri administration was followed by a significant decrease in the Gastrointestinal Symptom Rating Scale as compared to pretreatment value (p < .05) that was not present in those receiving placebo (p = not significant). No difference in eradication rates was observed. Conclusions: L. reuteri effectively suppresses H. pylori infection in humans and decreases the occurrence of dyspeptic symptoms. Nevertheless, it does not seem to affect antibiotic therapy outcome. |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Antigens, Bacterial) 8W8T17847W (Urea) |
| تواريخ الأحداث: | Date Created: 20080307 Date Completed: 20080421 Latest Revision: 20221207 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/j.1523-5378.2008.00593.x |
| PMID: | 18321302 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1523-5378 |
|---|---|
| DOI: | 10.1111/j.1523-5378.2008.00593.x |